Detalhe da pesquisa
1.
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Lancet Oncol
; 13(3): 239-46, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22285168
2.
Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study).
Lung Cancer
; 173: 83-93, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36162227